Figure 3 | Scientific Reports

Figure 3

From: Clinical implications of changes in the diversity of c-MYC copy number variation after neoadjuvant chemotherapy in breast cancer

Figure 3

Kaplan-Meier survival analyses based on c-MYC copy number variation (CNV) before and after neoadjuvant chemotherapy. In the pre-neoadjuvant chemotherapy (NAC) samples, c-MYC amplification (A) and copy number gain (B) were not associated with disease-free survival of the patients, while a high Shannon index for c-MYC CNV (C) shows a significant association with poor disease-free survival. Similarly, in the post-NAC samples, c-MYC amplification (D) and copy number gain (E) were not associated with disease-free survival, and a high Shannon index (F) shows a significant association with poor disease-free survival.

Back to article page